PL377657A1 - Ligand Ó-2-Ű do leczenia dolegliwości dolnych dróg moczowych - Google Patents

Ligand Ó-2-Ű do leczenia dolegliwości dolnych dróg moczowych

Info

Publication number
PL377657A1
PL377657A1 PL377657A PL37765703A PL377657A1 PL 377657 A1 PL377657 A1 PL 377657A1 PL 377657 A PL377657 A PL 377657A PL 37765703 A PL37765703 A PL 37765703A PL 377657 A1 PL377657 A1 PL 377657A1
Authority
PL
Poland
Prior art keywords
alpha
urinary tract
delta ligand
lower urinary
tract symptoms
Prior art date
Application number
PL377657A
Other languages
English (en)
Inventor
Charles Price Taylor Jr.
Andrew John Thorpe
Simon Lempriere Westbrook
David Juergen Wustrow
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32599054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL377657(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0302657A external-priority patent/GB0302657D0/en
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of PL377657A1 publication Critical patent/PL377657A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
PL377657A 2002-12-13 2003-12-03 Ligand Ó-2-Ű do leczenia dolegliwości dolnych dróg moczowych PL377657A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43349102P 2002-12-13 2002-12-13
GB0302657A GB0302657D0 (en) 2003-02-05 2003-02-05 Method of treatment

Publications (1)

Publication Number Publication Date
PL377657A1 true PL377657A1 (pl) 2006-02-06

Family

ID=32599054

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377657A PL377657A1 (pl) 2002-12-13 2003-12-03 Ligand Ó-2-Ű do leczenia dolegliwości dolnych dróg moczowych

Country Status (21)

Country Link
EP (2) EP1572173B1 (pl)
JP (2) JP2006511606A (pl)
KR (3) KR20050085563A (pl)
AT (1) ATE465725T1 (pl)
AU (2) AU2003303041B2 (pl)
BR (1) BR0316572A (pl)
CA (2) CA2509605C (pl)
CY (1) CY1110114T1 (pl)
DE (1) DE60332387D1 (pl)
DK (1) DK1572173T3 (pl)
ES (1) ES2341240T3 (pl)
MX (1) MXPA05006333A (pl)
MY (2) MY146794A (pl)
NO (1) NO20053355D0 (pl)
NZ (2) NZ539972A (pl)
PL (1) PL377657A1 (pl)
PT (1) PT1572173E (pl)
RU (2) RU2331438C2 (pl)
SI (1) SI1572173T1 (pl)
TW (1) TWI340639B (pl)
WO (1) WO2004054560A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60315258T2 (de) * 2002-12-20 2008-05-08 Dynogen Pharmaceuticals Inc., Waltham Behandlung von nicht-schmerzhaften blasenstörungen mit modulatoren der alpha-2-delta-untereinheit des calciumkanals
EP1621193A3 (en) * 2002-12-20 2006-08-02 Dynogen Pharmaceuticals Inc. Treatment of non-painful bladder disorders using alpha2-delta-subunit calcium channel modulators
US7223754B2 (en) 2003-03-10 2007-05-29 Dynogen Pharmaceuticals, Inc. Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders
US7084116B2 (en) 2003-03-10 2006-08-01 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using Cav2.2 subunit calcium channel modulators
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
ES2275229T3 (es) * 2003-03-21 2007-06-01 Dynogen Pharmaceuticals, Inc. Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
EP1663398B1 (en) * 2003-09-12 2009-11-25 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
EP1675582A1 (en) * 2003-09-12 2006-07-05 Warner-Lambert Company LLC Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
CA2595617C (en) * 2005-01-27 2014-06-03 Erimos Pharmaceuticals Llc Formulations for injection of catecholic butanes, including ndga compounds, into animals
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
WO2007072156A1 (en) * 2005-12-21 2007-06-28 Pfizer Products Inc. Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor
JP5308350B2 (ja) 2006-12-22 2013-10-09 レコルダーティ アイルランド リミテッド α２δリガンドおよびＮＳＡＩＤを用いた下部尿路機能障害の併用療法
KR101454167B1 (ko) 2007-09-07 2014-10-27 삼성전자주식회사 데이터 압축 및 복원 장치 및 방법
WO2009136375A1 (en) * 2008-05-08 2009-11-12 Pfizer Inc Treatment of interstitial cystitis
WO2010084798A1 (ja) * 2009-01-21 2010-07-29 第一三共株式会社 ３環性化合物
EP2994197B1 (en) 2013-05-06 2021-04-28 Kaohsiung Chang Gung Memorial Hospital Pharmaceutical combination of an nsaid and atropine
US20220002359A1 (en) 2017-05-26 2022-01-06 Novassay S.A. Voltage-Gated Calcium Channel Auxilliary Subunit Alpha 2 Delta and Uses Thereof

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3511836A (en) 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US4018830A (en) 1969-09-22 1977-04-19 Merck & Co., Inc. Phenylthioaralkylamines
US3840597A (en) 1971-02-24 1974-10-08 Riker Laboratories Inc Substituted 2-phenoxy alkane-sulfonanilides
JPS4966691A (pl) 1972-10-30 1974-06-27
NL175059C (nl) 1974-02-23 Boehringer Mannheim Gmbh Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4026894A (en) 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
GB1561411A (en) 1977-02-25 1980-02-20 Science Union & Cie 2-phenoxyphenyl pyrrolidines and pharmaceutical compositions containing them
US4188390A (en) 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
DE2756113A1 (de) 1977-12-16 1979-06-21 Thomae Gmbh Dr K Neue 4-hydroxy-2h-1,2-benzothiazin- 3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
FR2421888A1 (fr) 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US4885367A (en) 1987-11-19 1989-12-05 Taisho Pharmaceutical Co., Ltd. Sulfonanilide compounds
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
ZA923283B (en) 1991-05-29 1993-01-27 Akzo Nv Phenoxyphenyl derivatives
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9117716D0 (en) * 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
FR2687155B1 (fr) 1992-02-12 1995-05-19 Roussel Uclaf Nouveaux derives hexapeptidiques, procede de preparation et application a titre de medicaments de ces nouveaux derives.
IT1254469B (it) * 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
FI945426A0 (fi) 1992-05-20 1994-11-18 Univ Northwestern GABA- ja L-glutamiinihappoanalogit kohtauksenvastaiseen käsittelyyn
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
DK0595546T3 (da) 1992-10-28 1996-04-15 Shionogi & Co Benzylidenderivater
EP0600675B1 (en) 1992-12-02 1998-07-08 Kissei Pharmaceutical Co., Ltd. Indoline compounds for the treatment of dysuria
EP0759432A1 (en) 1993-01-15 1997-02-26 G.D. Searle & Co. Use of medicaments containing 3,4-diaryl furans and analogs thereof for treating a skin-related condition
CA2113787A1 (en) 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5475018A (en) 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
RU2139281C1 (ru) 1993-11-30 1999-10-10 Джи Ди Сирл энд Компани Пиразолилзамещенный бензолсульфонамид или его фармацевтически приемлемая соль, фармацевтическая композиция, способ лечения от воспаления или связанного с воспалением заболевания
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
JPH09512016A (ja) 1994-04-14 1997-12-02 メルク エンド カンパニー インコーポレーテッド α１Ｃアドレナリン受容体拮抗薬
US5418254A (en) 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
AU2424895A (en) 1994-05-04 1995-11-29 G.D. Searle & Co. Substituted spirodienes for the treatment of inflammation
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
JPH10504542A (ja) 1994-07-27 1998-05-06 ジー．ディー．サール アンド カンパニー 炎症処置用の置換チアゾール化合物
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5739166A (en) 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
JP3181190B2 (ja) 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
JP2636819B2 (ja) 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
ES2303337T3 (es) 1995-01-20 2008-08-01 G.D. Searle Llc Inhibidores de la proteasa retroviral de bis-hidroxietilamino sulfonamida.
US5596008A (en) 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
PL185544B1 (pl) 1995-02-13 2003-05-30 Nowa pochodna podstawionego izoksazolu i środek farmaceutyczny
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5731343A (en) 1995-02-24 1998-03-24 The Scripps Research Institute Method of use of radicicol for treatment of immunopathological disorders
CA2189355A1 (en) 1995-03-01 1996-09-06 Yasuo Onoda Imidazoquinazoline derivatives
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
AU5886296A (en) 1995-06-02 1996-12-18 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
AU715762B2 (en) 1995-07-21 2000-02-10 Nycomed Austria Gmbh Derivatives of benzosulphonamides as inhibitors of the enzyme cyclooxygenase II
ATE278399T1 (de) 1995-07-21 2004-10-15 Savvipharm Inc Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9520584D0 (en) 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
US5981576A (en) 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6020343A (en) 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6057319A (en) 1995-10-30 2000-05-02 Merck Frosst Canada & Co. 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
US6222048B1 (en) 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
DE69712877T2 (de) 1996-02-07 2002-11-14 Warner-Lambert Co., Morris Plains Zyklischaminosäure als pharmazeutische mittel
JP2000506862A (ja) 1996-03-14 2000-06-06 ワーナー―ランバート・コンパニー 医薬としての新規な架橋環状アミノ酸
SK283295B6 (sk) 1996-03-14 2003-05-02 Warner-Lambert Company Substituovaná cyklická aminokyselina, jej použitie a farmaceutický prostriedok na jej báze
US6180651B1 (en) 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
DK1288206T3 (da) 1996-04-12 2008-11-24 Searle Llc Substituerede benzensulfonamidderivater som prolægemidler af COX-2-inhibitorer
US5883267A (en) 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
EE03680B1 (et) 1996-07-18 2002-04-15 Merck Frosst Canada & Co. / Merck Frosst Canada &Cie. Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
NZ332762A (en) 1996-07-24 2000-09-29 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
JP3978250B2 (ja) * 1996-08-16 2007-09-19 株式会社フジモト・コーポレーション テストステロン５α−リダクターゼ阻害剤
JP2002514187A (ja) 1996-10-23 2002-05-14 ワーナー―ランバート・コンパニー 薬剤としての置換γ―アミノ酪酸
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
ATA16597A (de) 1997-02-03 1998-04-15 Nycomed Austria Gmbh Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide
US6136831A (en) 1997-04-11 2000-10-24 Grelan Pharmaceutical Co., Ltd. Pyrazole derivatives and COX inhibitors containing them
US6130334A (en) 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6127545A (en) 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
SK285991B6 (sk) * 1997-04-25 2008-01-07 Pfizer Inc. Pyrazolopyrimidinóny, spôsob a medziprodukty na ich výrobu, ich použitie a farmaceutické a veterinárne kompozície na ich báze
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CA2295021A1 (en) 1997-06-30 1999-01-28 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
AP9801302A0 (en) 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
AU8668598A (en) * 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
US6307047B1 (en) 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
HU226165B1 (en) * 1997-09-08 2008-05-28 Warner Lambert Co Analgesic compositions comprising anti-epileptic compounds and non-steroid anti-inflammatory dr4gs
US5925769A (en) 1997-09-09 1999-07-20 Ortho Pharmaceutical, Corp. Acetylenic 1,5-diarylpyrazoles as antiinflammatory agents
US6046217A (en) 1997-09-12 2000-04-04 Merck Frosst Canada & Co. 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
US6140515A (en) 1997-09-24 2000-10-31 Merck & Co., Inc. Process of making 3-aryloxy, 4-aryl furan-2-ones useful as inhibitors of COX-2
US6040450A (en) 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
CA2303244C (en) 1997-10-27 2005-12-06 Warner-Lambert Company Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
US6080876A (en) 1997-10-29 2000-06-27 Merck & Co., Inc. Process for making phenyl heterocycles useful as COX-2 inhibitors
US6133292A (en) 1997-10-30 2000-10-17 Merck Frosst Canada & Co. Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
HRP20020585B1 (hr) 1997-11-12 2013-02-28 Bayer Schering Pharma Aktiengesellschaft 2-fenil supstituirani imidazotriazinoni kao inhibitori fosfodiesteraze
KR20010033153A (ko) 1997-12-16 2001-04-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 4(3)-치환-4(3)-아미노메틸-(티오)피란 또는 -피페리딘유도체(=가바펜틴 동족체), 그의 제법 및 신경 질환 치료용도
JP2002508362A (ja) 1997-12-16 2002-03-19 ワーナー−ランバート・カンパニー １−置換−１−アミノメチル−シクロアルカン誘導体（＝ガバペンチン類縁体）、その製造および神経学的疾患の治療におけるその使用
TR200001794T2 (tr) 1997-12-16 2000-10-23 Warner-Lambert Company Farmasötik maddeler olarak yeni aminler
JP3256513B2 (ja) 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
US5994379A (en) 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
BR9909808A (pt) 1998-04-20 2000-12-26 Pfizer Pirazolopirimidinonas inibidoras de cgmp pde5 para o tratamento da disfunção sexual
WO1999061016A1 (fr) * 1998-05-27 1999-12-02 Nippon Shinyaku Co., Ltd. Inhibiteurs de cyclo-oxygenase-2
CA2320290A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of cyclooxygenase-2
EP0967777A3 (de) 1998-06-26 2000-01-05 Siemens Aktiengesellschaft Verfahren zur Übertragung von Informationen im Teilnehmeranschlussbereich
KR100295206B1 (ko) 1998-08-22 2001-07-12 서경배 디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물
WO2000012069A1 (en) * 1998-08-27 2000-03-09 Pharmacia & Upjohn Ab Therapeutic formulation for administering tolterodine with controlled release
CA2339630C (en) 1998-09-16 2006-05-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
EP1123296B1 (en) 1998-10-23 2003-09-17 Pfizer Limited PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
CZ300570B6 (cs) 1998-10-27 2009-06-17 Abbott Laboratories Inhibitory biosyntézy prostaglandin endoperoxid H synthasy
US6077869A (en) 1998-10-29 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
AP2001002252A0 (en) 1999-02-23 2001-09-30 Pfizer Prod Inc Monoamine reuptake inhibitors for treatment of CNS disorders.
ATE463242T1 (de) * 1999-04-08 2010-04-15 Warner Lambert Co Behandlung von inkontinenz
CA2374755C (en) 1999-06-10 2010-03-30 Warner-Lambert Company Mono- and disubstituted 3-propyl gamma-aminobutyric acids
US6376519B1 (en) 1999-06-16 2002-04-23 Temple University-Of The Commonwealth Of Higher Education 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2
MXPA00006605A (es) 1999-07-02 2004-12-09 Pfizer Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
US6077868A (en) 1999-07-20 2000-06-20 Wisconsin Alumni Research Foundation Selective inhibition of cyclooxygenase-2
US6306890B1 (en) 1999-08-30 2001-10-23 Vanderbilt University Esters derived from indolealkanols and novel amides derived from indolealkylamides that are selective COX-2 inhibitors
CA2323008C (en) 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
CZ20021151A3 (cs) 1999-10-11 2003-03-12 Pfizer Inc. 5-(2-substituovaný-5-heterocyklylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]-pyrimidin-7-ony jako inhibitory fosfodiesterasy
NZ517696A (en) 1999-10-13 2004-12-24 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors
HN2000000224A (es) 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
US6083969A (en) 1999-10-20 2000-07-04 Ortho-Mcneil Pharaceutical, Inc. 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
IL139073A0 (en) * 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
HK1054196B (zh) * 1999-11-11 2008-08-01 法马西雅公司 含托特罗定的药物制剂及其应用
GB2362646A (en) 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
EP1289989A2 (en) 2000-06-07 2003-03-12 Lilly Icos LLC Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
WO2001094347A1 (en) 2000-06-08 2001-12-13 Lilly Icos Llc Tetracyclic diketopiperazine compounds as pdev inhibitors
AU2001266575A1 (en) 2000-06-26 2002-01-08 Lilly Icos Llc Chemical compounds
DE10035718A1 (de) 2000-07-21 2002-02-07 Boehringer Werkzeugmaschinen Werkzeugmaschine
GB2365425A (en) 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
US7034027B2 (en) 2000-08-02 2006-04-25 Lilly Icos Llc Fused heterocyclic derivatives as phosphodiesterase inhibitors
PL361424A1 (pl) 2000-09-14 2004-10-04 Grünenthal GmbH beta-tioaminokwasy
DE10048715A1 (de) 2000-09-30 2004-05-19 Grünenthal GmbH Verwendung von Aminosäure zur Behandlung von Schmerz
AR034160A1 (es) 2000-09-30 2004-02-04 Gruenenthal Gmbh Sulfonilguanidinas, medicamentos que contienen estos compuestos y el uso de sulfonilguanidinas
US6962918B2 (en) 2000-10-02 2005-11-08 Lilly Icos Llc. Hexahydropyrazino[1'2';1,6]pyrido[3,4-b]indole-1,4-diones for the treatment of cardiovascular disorders and erectile dysfunction
AU2002213419A1 (en) 2000-10-02 2002-04-15 Lilly Icos Llc Condensed pyridoindole derivatives
ES2267831T3 (es) 2000-10-03 2007-03-16 Lilly Icos Llc Derivados de piridoindol condensado.
US6992076B2 (en) 2000-10-06 2006-01-31 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
GB2367869B (en) 2000-10-14 2004-10-06 Trw Ltd Rear-axle demand for use with front push-through in electrohydraulic (EHB) braking systems
US6359182B1 (en) 2000-10-26 2002-03-19 Duke University C-nitroso compounds and use thereof
GB2368579A (en) 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
CA2427573C (en) 2000-11-06 2008-10-07 Lilly Icos Llc Indole derivatives as pde5-inhibitors
ATE293111T1 (de) 2000-11-08 2005-04-15 Lilly Icos Llc Kondensierte pyrazindionderivate als pde inhibitoren
AU2002239257A1 (en) 2000-11-17 2002-06-03 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
SK6092003A3 (en) * 2000-11-30 2004-07-07 Pfizer Prod Inc Combination of GABA agonists and aldosereductase inhibitors
MXPA03007140A (es) 2001-02-12 2004-05-24 Lilly Icos Llc Derivados de carbolina.
GB0105893D0 (en) 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
BR0208078A (pt) 2001-03-16 2004-03-02 Pfizer Compostos pirazol[4,3-d]pirimidinona como inibidores de cgmp pde
GB0106631D0 (en) 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
GB0106661D0 (en) 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
DE60235619D1 (de) 2001-04-19 2010-04-22 Warner Lambert Co Kondensierte bizyklische oder trizyklische aminosäuren
KR200245823Y1 (ko) 2001-06-08 2001-10-22 김영남 물감튜브가 달린 그림붓
DE10127980C1 (de) 2001-06-08 2003-01-16 Ovd Kinegram Ag Zug Diffraktives Sicherheitselement
CA2449729C (en) 2001-06-11 2009-11-03 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
PL372210A1 (pl) * 2002-02-22 2005-07-11 Warner-Lambert Company Llc Połączenia alfa-2-delta ligandu z selektywnym inhibitorem cyklooksygenazy-2
US7892837B2 (en) 2002-05-23 2011-02-22 Karsten Koenig Method for transferring molecules in vital cells by means of laser beams and arrangement for carrying out said method
DE60315258T2 (de) 2002-12-20 2008-05-08 Dynogen Pharmaceuticals Inc., Waltham Behandlung von nicht-schmerzhaften blasenstörungen mit modulatoren der alpha-2-delta-untereinheit des calciumkanals
ES2275229T3 (es) * 2003-03-21 2007-06-01 Dynogen Pharmaceuticals, Inc. Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.
CN112585695B (zh) 2018-08-16 2025-05-16 生命技术公司 用于自动化试剂验证的系统和方法

Also Published As

Publication number Publication date
ES2341240T3 (es) 2010-06-17
EP2196201A3 (en) 2010-12-08
RU2008108841A (ru) 2009-09-20
RU2331438C2 (ru) 2008-08-20
TWI340639B (en) 2011-04-21
HK1083010A1 (zh) 2006-06-23
CA2509605C (en) 2010-10-05
CY1110114T1 (el) 2015-01-14
JP2011168606A (ja) 2011-09-01
WO2004054560A1 (en) 2004-07-01
NZ567457A (en) 2009-08-28
EP1572173B1 (en) 2010-04-28
NO20053355L (no) 2005-07-11
AU2003303041B2 (en) 2008-07-24
MY146794A (en) 2012-09-28
JP2006511606A (ja) 2006-04-06
DK1572173T3 (da) 2010-06-14
SI1572173T1 (sl) 2010-08-31
MY141007A (en) 2010-02-12
KR20090118994A (ko) 2009-11-18
CA2509605A1 (en) 2004-07-01
AU2003303041A1 (en) 2004-07-09
AU2008233202A1 (en) 2008-11-13
RU2005118071A (ru) 2006-01-27
BR0316572A (pt) 2005-10-04
NO20053355D0 (no) 2005-07-11
AU2008233202B2 (en) 2011-02-24
NZ539972A (en) 2008-05-30
EP1572173A1 (en) 2005-09-14
PT1572173E (pt) 2010-05-10
KR20070091049A (ko) 2007-09-06
MXPA05006333A (es) 2005-08-26
CA2679030A1 (en) 2004-07-01
TW200424153A (en) 2004-11-16
EP2196201A2 (en) 2010-06-16
ATE465725T1 (de) 2010-05-15
KR20050085563A (ko) 2005-08-29
DE60332387D1 (de) 2010-06-10

Similar Documents

Publication Publication Date Title
CY1110114T1 (el) Προσδετης αλφα-2-δελτα για την αγωγη των συμπτωματων του κατωτερου ουροποιητικου συστηματος
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
GB0111523D0 (en) Chemical compounds
IL160420A0 (en) Treating or preventing diabetes with cannabidiol
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
UA85597C2 (ru) Четвертичные соли как антагонисты ccr2
PT2383271E (pt) Aminoquinolonas como inibidores de gsk-3
IL210046A0 (en) Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease
WO2005089753A3 (en) Daao inhibiting bξnzisoxazoles and their use for the treatment of mental disorders
AP2004002997A0 (en) Heterocyclic compounds for use in the treatment ofdisorders of the urinary tract.
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
ZA200604114B (en) Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease
PT1855677E (pt) 3-11b-cis-di-hidrotetrabenazina para o tratamento da esquizofrenia e de outras psicoses
MA27566A1 (fr) Inhibiteurs de 4-oxo-1-(3-phenyle substitue -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4
MY142804A (en) Nk1 antagonists
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
WO2008032222A3 (en) Treatment of vertigo with acetyl-l-leucine
NZ546440A (en) Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
MXPA03006412A (es) Metodos para administrar analogos de epotilona para tratamiento de cancer.
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2003273856A1 (en) Vr1 antagonists for the treatment of urological disorders

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)
VDSO Invalidation of derivated patent or utility model

Ref document number: 391987

Country of ref document: PL

Kind code of ref document: A1